explore -WSS

explore

author：focus 2025-09-02 05:46:00 - browse：8138

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Hospitals warn Medicare's drug payment fix is ‘unlawful’

entertainment

WSS

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Biden's order seeks to regulate AI risk without stifling innovation

FDA has safety concerns on CRISPR

Xenotransplantation trials will require adjusting expectations, experts say

Cassava reveals details — and problems — with Alzheimer's study

Can medical device makers keep up in the race to treat obesity?

focus

explore

explore

Affirmative action in medical school literally saved lives

Inside the rise of 'mukbang' eating videos

DIEP, the 'gold standard' of breast reconstruction, is under threat

Physician subsidies by hospitals soar in wake of No Surprises Act

Peter Hotez and the public health issue of online harassment

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Cancer drug shortages should be causing more outrage

Emergency medicine has repudiated 'excited delirium.' Now what?

As demand for Covid shots wanes, Moderna seeks its next success

Patients, doctors are clashing about side effects of hormonal birth control

knowledge

Eli Lilly to pay $200M for Beam’s stake in gene

Biogen nominates mother of director’s child to replace him on board

Meta's Zuckerberg and Chan on track to put $50 billion into science

Novo pauses ads for weight loss drug Wegovy amid demand

Senate panel passes drug pricing bills, but drops one PBM reform

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

entertainment

Wikipedia

hotspot

focus